Cargando…
Changes in the utilization of osteoporosis drugs after the 2010 FDA bisphosphonate drug safety communication
INTRODUCTION: In October 2010, the US Food and Drug Administration (FDA) issued a safety communication regarding the risks of atypical fractures of the femur, with bisphosphonates drugs. This study evaluated the impact of the bisphosphonates FDA safety communication on the utilization of osteoporosi...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6111194/ https://www.ncbi.nlm.nih.gov/pubmed/30166922 http://dx.doi.org/10.1016/j.jsps.2017.12.005 |